<DOC>
	<DOCNO>NCT00496158</DOCNO>
	<brief_summary>The objective study compare nucleoside treatment-naïve subject , efficacy safety clevudine 30 mg daily versus adefovir 10 mg daily , monotherapy , 48 week , 72 week , 96 week .</brief_summary>
	<brief_title>Efficacy Safety Clevudine Compared With Adefovir Patients With Chronic Hepatitis Due Hepatitis B Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>Nucleoside treatmentnaïve subject either gender , female nonpregnant nonlactating , age 16 year old ( legal age consent allow local regulation ) , compensate hepatic function despite diagnosis chronic HBeAg negative hepatitis B infection ( i.e. , base serological , virological histological marker ) eligible study . Subjects enter study historical biopsy chronic hepatic inflammatory injury screening ( Knodell HAI score ≥ 4 modify Ishak fibrosis score ≤ 5 ) . The number subject enter study Ishak fibrosis score 5 limit approximately 10 % . If applicable , subject must cease previous treatment form alpha interferon 12 month prior baseline . For eligibility , subject must meet laboratory criterion total bilirubin , prothrombin time , serum albumin , platelet count , absolute neutrophil count , ANA titer creatinine clearance ≥ 50 mL/min . Subjects participate clinical trial receive investigational agent reason within 60 day baseline exclude . Subjects clinically significant concomitant disease exclude .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Nucleoside Treatment-Naïve Patients HBeAg Negative Chronic Hepatitis due Hepatitis B Virus</keyword>
	<keyword>hepatitis b virus</keyword>
</DOC>